Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

172.45USD
20 Jan 2017
Change (% chg)

$-1.07 (-0.62%)
Prev Close
$173.52
Open
$173.78
Day's High
$174.34
Day's Low
$172.18
Volume
1,068,781
Avg. Vol
1,061,842
52-wk High
$181.76
52-wk Low
$129.50

Latest Key Developments (Source: Significant Developments)

Becton Dickinson and Co gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:00am EST 

Becton Dickinson and Co:Continues to estimate that currency-neutral adjusted revenues for FY 2016, including accretion from acquisition of CareFusion, will increase 24.5 to 25.0 percent. Including the impact of foreign currency, as adjusted and as reported, revenues are now expected to increase 20.0 to 20.5 percent.Says this is a decrease from previously issued guidance of 23.0 to 23.5 percent growth.On a comparable, currency-neutral basis, the company continues to estimate organic adjusted revenues will increase 4.5 to 5.0 percent.Continues to expect adjusted diluted earnings per share to be between $8.37 and $8.44 for FY 2016 including estimated unfavorable impact from foreign currency.Says on a currency-neutral basis, the company now expects FY 2016 adjusted diluted earnings per share to be between $9.01 and $9.08, which represents growth of about 26.0 to 27.0 percent over FY 2015 adjusted diluted earnings per share of $7.16.Says this is an increase from previously issued currency-neutral guidance of $8.73 to $8.80 which represented approximately 22.0 to 23.0 percent growth.As reported, the Company expects full fiscal year diluted earnings per share to be between $6.23 and $6.30.  Full Article

Becton Dickinson and Co divests BD Rx Business
Friday, 8 Jan 2016 08:05am EST 

Becton Dickinson and Co:Says Fresenius Kabi USA has acquired the BD Rx business.Additional financial and contractual terms of the transactions were not disclosed.BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement under which Fresenius Kabi will supply BD with a portfolio of intravenous solutions.Both BD and Fresenius Kabi plan to offer a range of IV solutions in the U.S. beginning in 2016.Expects the divestiture of BD Rx to be modestly accretive to fiscal 2016 adjusted diluted earnings per share.  Full Article

Becton Dickinson and Co declares quarterly dividend
Monday, 23 Nov 2015 05:25pm EST 

Becton Dickinson and Co:Declares quarterly dividend of $0.66 cents per common share, an increase of 10.0 percent from the previous quarter.Payable on Dec. 31 to holders of record on Dec. 10.  Full Article

Becton Dickinson and Co's CareFusion AirLife signs new distribution agreement with ResMed Inc
Thursday, 5 Nov 2015 06:59am EST 

Becton Dickinson and Co's CareFusion:Says its Air Life business line has signed an exclusive agreement with ResMed to distribute innovative nasal high flow interface products from the company.Additional terms of the agreement were not disclosed.Agreement with ResMed includes exclusive distribution rights for its Acu Care high flow nasal cannula in the U.S. acute care market.  Full Article

Becton Dickinson and Co gives FY 2016 EPS guidance
Wednesday, 4 Nov 2015 06:00am EST 

Becton Dickinson and Co:Expects adjusted diluted earnings per share to be between $8.37 and $8.44 for the FY 2016 including the estimated unfavorable impact from foreign currency.FY 2016 EPS of $8.39 - Thomson Reuters I/B/E/S.  Full Article

Becton Dickinson and Co's BD MAX Enteric Parasite Panel Receives FDA Clearance
Thursday, 24 Sep 2015 08:30am EDT 

Becton Dickinson and Co:Says BD Life Sciences, a segment of the availability announced the U.S. Food and Drug Administration (FDA) cleared BD MAX Enteric Parasite Panel for use on the BD MAX System.  Full Article

Becton, Dickinson and Company raising FY 2015 adjusted diluted earnings per share
Thursday, 6 Aug 2015 06:30am EDT 

Becton, Dickinson and Company:Says that it is raising FY 2015 adjusted diluted earnings per share guidance to a range of $7.08 to $7.12.  Full Article

Becton, Dickinson and Company declares dividend
Tuesday, 28 Jul 2015 04:05pm EDT 

Becton, Dickinson and Company:Declared a quarterly dividend of 60 cents per common share, payable on September 30, 2015 to holders of record on September 9, 2015.  Full Article

MEDINET signs licensing contract with Becton, Dickinson and Company
Monday, 22 Jun 2015 02:00am EDT 

MEDINET Co Ltd:Signs a licensing contract with Becton, Dickinson and Company (BD).To develop product using monoclonal antibody through the license agreement, and make the new monoclonal antibody commercialized.  Full Article

Becton, Dickinson and Co's Carefusion Provides Update on Voluntary Global Recall of Avea Ventilator - FDA
Tuesday, 26 May 2015 08:00pm EDT 

Becton Dickinson and Co:Provides an update on a global voluntary recall that was initiated on April 21, to address an issue with certain units of AVEA ventilators - FDA.Says the recall has been designated as a Class I recall by the FDA, which means the Agency believes that there is a reasonable probability that use of the recalled product will cause serious adverse health consequences or death.To date, no report of patient injury has been received related to this issue.Says the global recall involves AVEA ventilators manufactured, serviced and distributed from July 1, 2011 to March 15.  Full Article

Becton Dickinson wins reversal of $340 million syringe award

A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co to pay rival Retractable Technologies Inc $340 million in damages over its marketing of safety syringes.